| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
49,056 |
42,789 |
$3.04M |
| 99199 |
Unlisted special service, procedure or report |
270,269 |
148,463 |
$1.68M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,101 |
15,161 |
$1.56M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,449 |
5,811 |
$596K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29,067 |
26,432 |
$580K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
14,106 |
12,778 |
$538K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,767 |
4,237 |
$405K |
| 0240U |
|
2,618 |
2,161 |
$359K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,434 |
2,233 |
$226K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,529 |
1,284 |
$210K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
10,764 |
9,737 |
$113K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,320 |
2,903 |
$98K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,256 |
989 |
$90K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,228 |
2,152 |
$58K |
| D0145 |
Oral evaluation for a patient under three years of age |
1,577 |
1,430 |
$54K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,162 |
1,001 |
$46K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
766 |
637 |
$38K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
363 |
319 |
$38K |
| D1206 |
Topical application of fluoride varnish |
1,566 |
1,419 |
$24K |
| 92551 |
|
13,421 |
12,181 |
$17K |
| 99173 |
|
16,781 |
15,295 |
$17K |
| 90474 |
|
848 |
770 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,249 |
1,223 |
$17K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,472 |
1,326 |
$14K |
| 99070 |
|
1,422 |
1,372 |
$13K |
| 90686 |
|
8,065 |
7,398 |
$12K |
| 99401 |
|
327 |
274 |
$10K |
| 0001A |
|
126 |
125 |
$8K |
| 0002A |
|
128 |
122 |
$8K |
| 96161 |
|
2,196 |
1,952 |
$8K |
| 94010 |
|
256 |
238 |
$6K |
| 0071A |
|
94 |
75 |
$5K |
| 0072A |
|
83 |
70 |
$5K |
| 83655 |
|
194 |
168 |
$3K |
| 94760 |
|
15,597 |
13,668 |
$3K |
| 36416 |
|
2,340 |
2,159 |
$2K |
| 80061 |
Lipid panel |
132 |
123 |
$2K |
| 96127 |
|
435 |
369 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
109 |
103 |
$1K |
| 96160 |
|
294 |
278 |
$998.58 |
| 90651 |
|
76 |
70 |
$910.48 |
| 90734 |
|
59 |
52 |
$868.86 |
| 90620 |
|
16 |
12 |
$826.24 |
| 90716 |
|
202 |
174 |
$278.04 |
| 36415 |
Collection of venous blood by venipuncture |
76 |
57 |
$180.28 |
| 90633 |
|
356 |
320 |
$136.18 |
| 90656 |
|
627 |
592 |
$61.55 |
| 90680 |
|
868 |
788 |
$0.00 |
| 90723 |
|
1,368 |
1,243 |
$0.00 |
| 99000 |
|
3,670 |
3,286 |
$0.00 |
| 90647 |
|
1,256 |
1,118 |
$0.00 |
| 91307 |
|
113 |
96 |
$0.00 |
| 90677 |
|
192 |
188 |
$0.00 |
| 87999 |
|
2,219 |
2,147 |
$0.00 |
| 90670 |
|
3,165 |
2,822 |
$0.00 |
| 90685 |
|
28 |
28 |
$0.00 |
| 90707 |
|
145 |
125 |
$0.00 |
| 91300 |
|
256 |
200 |
$0.00 |